Proteomics Firm Power3 Delisted from OTC Board for Failure to File Annual Report | GenomeWeb

NEW YORK. June 16 (GenomeWeb News) - Nasdaq has notified proteomics firm Power3 Medical Products that its common stock will be delisted from the Over-the-Counter Bulletin Board effective today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.